Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 5, 2001, Pages 651-656

  Gajdoš, Martin ^a   Mongiellová, Viera ^a   Huttová, Dagmar ^a   Cibulová, Lubica ^a   Krivošíková, Zora ^a   Spustová, Viera ^a   Dzúrik, Rastislav ^a  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

Author keywords

Aspirin; Atherosclerosis; Ciprofibrate; Plaque stabilization; Platelet derived growth factor AB; Proliferation; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CIPROFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLATELET DERIVED GROWTH FACTOR AB; THROMBOXANE B2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOLIPEMIA; MALE; PRIORITY JOURNAL; THROMBOCYTOPOIESIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; ASPIRIN; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET-DERIVED GROWTH FACTOR;

EID: 0034776182     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200111000-00001     Document Type: Article

References (19)

1. The biochemical pharmacology of fenofibrate
2. Activation of human aortic smooth-muscle cells is inhibited by PPARalfa but not by PPARgamma activators
3. Growth inhibition of human vascular smooth muscle cells by fenofibrate: A possible therapy for restenosis
4. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice
5. Multicenter comparison of micronised fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia
6. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NFkappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells
7. The nuclear factor kappa-B signalling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis
8. Participation of the platelet derived growth factor (PDGF) in the progression of nephropathies
9. Cell biology of platelet-derived growth factor
10. Platelet-derived growth factor and arterial response to injury
11. Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets
12. The effect of ciprofibrate in monotherapy and combination with acetylsalicylic acid on lipid parameters, thromboxane and fibrinogen in patients with advanced atherosclerosis and hyperlipoproteinemia
13. Mechanism of action of platelet derived growth factor
14. Platelet-derived growth factor
15. Optimal dose for starting and maintaining low-dose aspirin
16. Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation
17. Role of plateletderived growth factor in glomerular disease
18. New insight into plaque stabilization by lipid lowering
19. Is vascular smooth muscle cell proliferation beneficial?